Umachanger Janani Kantharooban, Zacho Helle Damgaard, Sylvest Camilla, Frandsen Anna Poulsgaard, Bentestuen Morten
From the Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital.
Departments of Gynecology and Obstetrics.
Clin Nucl Med. 2025 Feb 1;50(2):e124-e126. doi: 10.1097/RLU.0000000000005537. Epub 2024 Oct 30.
A 54-year-old woman presented with a 55 × 64-mm tumor in the ovary with high [ 18 F]FDG uptake on [ 18 F]FDG PET/CT highly suggestive of ovarian cancer. Prior to surgery, the patient underwent [ 68 Ga]-Ga- fibroblast activation protein inhibitor (FAPI)-46 PET/CT, which revealed low [ 68 Ga]-Ga-FAPI-46 tumor uptake. Histopathology revealed a borderline ovarian tumor, which has low malignant potential and a 10-year survival rate greater than 93%. High [ 18 F]FDG uptake is considered a fair predictor of malignancy in adnexal tumors. The present case demonstrates the potential superiority of [ 68 Ga]-Ga-FAPI-46 PET/CT over [ 18 F]-FDG PET/CT in differentiating malignant adnexal tumors from borderline ovarian tumors.
一名54岁女性，卵巢有一个55×64毫米的肿瘤，[18F]FDG PET/CT显示该肿瘤[18F]FDG摄取高，高度提示卵巢癌。手术前，患者接受了[68Ga] - 镓 - 成纤维细胞激活蛋白抑制剂（FAPI）-46 PET/CT检查，结果显示[68Ga] - 镓 - FAPI-46肿瘤摄取低。组织病理学显示为交界性卵巢肿瘤，其恶性潜能低，10年生存率大于93%。[18F]FDG摄取高被认为是附件肿瘤恶性程度的一个合理预测指标。本病例证明了[68Ga] - 镓 - FAPI-46 PET/CT在区分恶性附件肿瘤与交界性卵巢肿瘤方面可能优于[18F] - FDG PET/CT。
